Page last updated: 2024-11-07

diazene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID123195
CHEBI ID30096
MeSH IDM0116757

Synonyms (24)

Synonym
(z)-diazene
15626-43-4
15626-42-3
diimide
CHEBI:30096
diazene
3618-05-1
hn=nh
diazene, cis
(z)-hn=nh
(e)-diazene
(e)-hn=nh
diimine
C05360
lm321pyv3y ,
unii-lm321pyv3y
diimide (n2h2)
DTXSID00189748
Q423323
RAABOESOVLLHRU-UHFFFAOYSA-N
diazene, (1e)-
DTXSID901336326
diazene, (1z)-
DTXSID201336325
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitrogen hydride
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
isoniazid activation110

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.56)18.7374
1990's6 (9.38)18.2507
2000's22 (34.38)29.6817
2010's30 (46.88)24.3611
2020's5 (7.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.03 (24.57)
Research Supply Index4.17 (2.92)
Research Growth Index5.43 (4.65)
Search Engine Demand Index61.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]